DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701

Completed

Conditions studied: Lymphoma

In brief

This research trial studies deoxyribonucleic acid (DNA) analysis in predicting response to antibody therapy in patients with follicular lymphoma treated on clinical trials Cancer and Leukemia Group B (CALGB)-50402 or CALGB-50701. Studying samples of blood from patients with follicular lymphoma in the laboratory may help doctors predict how well patients will respond to treatment.

Key facts

Study ID

NCT01057459

Run by

Alliance for Clinical Trials in Oncology

People needed

78

Starts

2010-02-01

Expected to finish

2014-06-23

Last updated by the study team

2017-06-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Untreated follicular lymphoma
• Has received rituximab-containing monoclonal antibody therapy on CALGB-50402 or CALGB-50701
• Patients have previously provided informed consent allowing correlative studies on genomic DNA

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.